- Home
- IMXI vs ANAB Comparison
IMXI vs ANAB Comparison
Compare IMXI & ANAB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMXI
- ANAB
- Stock Information
- Founded
- IMXI 1994
- ANAB 2005
- Country
- IMXI United States
- ANAB United States
- Employees
- IMXI N/A
- ANAB N/A
- Industry
- IMXI Retail: Computer Software & Peripheral Equipment
- ANAB Biotechnology: Pharmaceutical Preparations
- Sector
- IMXI Technology
- ANAB Health Care
- Exchange
- IMXI Nasdaq
- ANAB Nasdaq
- Market Cap
- IMXI 302.5M
- ANAB 621.1M
- IPO Year
- IMXI N/A
- ANAB 2017
- Fundamental
- Price
- IMXI $10.30
- ANAB $26.55
- Analyst Decision
- IMXI Buy
- ANAB Buy
- Analyst Count
- IMXI 7
- ANAB 10
- Target Price
- IMXI $19.60
- ANAB $44.25
- AVG Volume (30 Days)
- IMXI 318.6K
- ANAB 499.6K
- Earning Date
- IMXI 08-06-2025
- ANAB 08-04-2025
- Dividend Yield
- IMXI N/A
- ANAB N/A
- EPS Growth
- IMXI 1.60
- ANAB N/A
- EPS
- IMXI 1.70
- ANAB N/A
- Revenue
- IMXI $652,547,000.00
- ANAB $111,872,000.00
- Revenue This Year
- IMXI N/A
- ANAB N/A
- Revenue Next Year
- IMXI $3.03
- ANAB $24.39
- P/E Ratio
- IMXI $6.02
- ANAB N/A
- Revenue Growth
- IMXI N/A
- ANAB 387.20
- 52 Week Low
- IMXI $9.76
- ANAB $12.21
- 52 Week High
- IMXI $22.38
- ANAB $41.31
- Technical
- Relative Strength Index (RSI)
- IMXI 45.01
- ANAB 70.24
- Support Level
- IMXI $10.22
- ANAB $23.10
- Resistance Level
- IMXI $10.87
- ANAB $26.17
- Average True Range (ATR)
- IMXI 0.34
- ANAB 1.33
- MACD
- IMXI 0.05
- ANAB 0.27
- Stochastic Oscillator
- IMXI 48.65
- ANAB 100.00
About IMXI International Money Express Inc.
International Money Express Inc is a processor of money transfer services in the USA to the Latin America and the Caribbean (LAC) corridor. The company offers wire transfer, money order, Foreign exchange, and cash checking services, while the majority of the revenue is derived from wire transfer and money order fees. The firm's business is organized around one reportable segment that provides money remittance services between the U.S. and Canada to Mexico, Guatemala, and other countries in Latin America, Africa, and Asia.
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).